Eagle Pharmaceuticals, Inc.

Total Valuation

Eagle Pharmaceuticals, Inc. carries a market capitalization of 6.05M, placing it among publicly traded companies globally. Its enterprise value stands at 310.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Eagle Pharmaceuticals, Inc. currently has 13.09M shares outstanding.

Valuation Ratios

Eagle Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 21.29. The price-to-sales ratio is 0.99, and the price-to-book ratio stands at 2.08.

Enterprise Valuation

On an enterprise value basis, Eagle Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 5.04 and an EV/FCF ratio of 29.99. The EV/Sales ratio of 1.21 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.57 provides insight into valuation relative to core operating earnings.

Financial Position

Eagle Pharmaceuticals, Inc. maintains a current ratio of 2.16, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.41, indicating elevated leverage, while an interest coverage ratio of 9.50 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Eagle Pharmaceuticals, Inc. posts a return on equity of 10.26 and a return on invested capital of 5.36.

Taxes

Over the trailing twelve months, Eagle Pharmaceuticals, Inc. has paid 17.22M in income taxes, reflecting an effective tax rate of 59.04.

Stock Price Statistics

Eagle Pharmaceuticals, Inc.'s stock has declined approximately -78.09524% over the past 52 weeks. The 50-day moving average sits at 0.46, while the 200-day moving average is 1.94.

Income Statement

Over the trailing twelve months, Eagle Pharmaceuticals, Inc. generated 257.55M in revenue and converted that into 11.95M in net income, yielding earnings per share of 0.91. EBITDA reached 61.63M, while operating income came in at 41.01M.

Balance Sheet

Eagle Pharmaceuticals, Inc. holds 15.35M in cash and equivalents against 71.62M in total debt, resulting in a net debt position of 54.84M. Total book value stands at 122.44M, with working capital of 100.62M providing operational flexibility.

Cash Flow

Eagle Pharmaceuticals, Inc. produced -9.32M in operating cash flow over the past twelve months. After subtracting -74,000.00 in capital expenditures, free cash flow totaled -9.39M - equivalent to -0.72 per share.

Margins

Eagle Pharmaceuticals, Inc. operates with a gross margin of 69.84, reflecting its pricing power and cost economics. The operating margin of 15.92 and net profit margin of 4.64 provide insight into operational efficiency.

Dividends & Yields

Scores

Eagle Pharmaceuticals, Inc. posts an Altman Z-Score of 3.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.